| Name | Title | Contact Details |
|---|
Grant Regional Health Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Grant Regional Health Center is based in Lancaster, WI. You can find more information on Grant Regional Health Center at www.grantregional.com
We launched Absolute Insight in 2016 to empower business users in the healthcare sector, where our clients have used it to alleviate the opioid crisis, curb waste in the healthcare system, and target fraudulent entities. As an industry agnostic platform, we`ve began to expand our service across other verticals, fulfilling our mission to become the global gateway for business users to leverage advanced analytics and artificial intelligence at scale. With a deep understanding of your company`s pain points and a platform that makes advanced analytics truly easy, your business users can create data-driven actionable insights and automated pipelines. As data continues to double every two years, this solution is necessary across all industries. Make your data your best asset, and empower your employees with computational resources and algorithms to free them up to pursue more creative work.
At Health IQ, we believe the best way to improve the health of the world is to celebrate the health conscious rather than harassing those who are not.
Thorek Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Thorek Memorial Hospital is based in Chicago, IL. You can find more information on Thorek Memorial Hospital at www.thorek.org
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.